**Table S5**: Prostate cancer (PCa) risk profiles among Black men and Non-Hispanic White (NHW) men diagnosed with first primary invasive PCa between 2004 and 2013 in California, using 4 risk categorizations (prostate specific antigen [PSA]1, Gleason score [GS]2, clinical stage3, and National Comprehensive Cancer Network [NCCN] PCa risk category4, fully adjusted models●; sensitivity analyses with period before and after the United States Preventive Services Task Force (USPSTF) recommendations as an indicator variable

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Characteristics |   | PSA1 |   | GS2 |   | Stage3 |  | Risk4 |
|   | OR | (95% CI) |   | OR | (95% CI) |   | OR | (95% CI) |  | OR | (95% CI) |
| Race |   |   |   |   |   |   |   |  |  |  |  |  |
|  NHW men |   | 1.00 | (Reference) |   | 1.00 | (Reference) |   | 1.00 | (Reference) |  | 1.00 | (Reference) |
|  Black men |   | 1.65 | (1.58-1.72) |   | 1.13 | (1.08-1.18) |   | 1.12 | (1.07-1.17) |  | 1.27 | (1.23-1.32) |
| Year of diagnosis (cont.) |  | 1.01 | (1.00-1.01) |  | 1.03 | (1.03-1.04) |   | 1.05 | (1.05-1.06) |  | 1.03 | (1.02-1.03) |
| Year of diagnosis before USPSTF |  |  |  |  |  |  |   |  |  |  |  |  |
|  Yes |  |  1.00 | (Reference) |   | 1.00 | (Reference) |   | 1.00 | (Reference) |  | 1.00 | (Reference) |
|  No |  | 1.35 | (1.27-1.43) |  | 1.26 | (1.20-1.33) |   | 1.24 | (1.17-1.31) |  | 1.30 | (1.24-1.36) |
| Total men included in analysis |   |  N = 153,398 |   | N = 160,648 |  |  N = 165,341 |  | N = 153,708 |
| ●All models adjusted for age at diagnosis, year of diagnosis, marital status, insurance type, and neighborhood socioeconomic status (nSES) |  |  |  |  |  |
| 1 PSA risk category low (≤20 ng/ mL) vs. high (>20 ng/ mL) |  |  |  |  |  |
| 2 GS risk category low (<8) vs. high (8+) |  |  |  |  |  |
| 3 Stage risk categories low (N0, M0, and <T2b) and high (N1, M1, and/ or T2b+)4 PCa risk stratification criteria based on the NCCN classification using TNM stage, GS and PSA level. Low included low-risk (T1/T2a and GS ≤ 6 and PSA<10 ng/ml) and intermediate-risk (T2b/T2c or biopsy GS 7 or PSA 10-20 ng/ml); and high included high-risk (T3/T4 or GS 8+ or PSA>20 ng/ml or N1 or M1). |  |